Navigation Links
Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
Date:1/5/2009

under-served medical markets, while SUPPRELIN LA and octreotide use the patented HYDRON drug delivery technology which may also have utility in pain management."

SUPPRELIN LA is a currently marketed product that provides a continuous, 12-month, controlled dose of histrelin to treat central precocious puberty. It employs the HYDRON Implant, a subcutaneous, retrievable, non-biodegradable, hydrogel reservoir drug delivery device designed to provide sustained release of a broad spectrum of drugs continuously, at constant, predetermined rates. The HYDRON Implant is the only soft, flexible, reservoir-based drug delivery system designed for easy, in-office physician insertion under local anesthesia.

NEBIDO is a novel, long-acting injectable testosterone depot being developed for the treatment of male hypogonadism. Indevus is currently preparing a complete response for submission to the U.S. Food and Drug Administration in the first half of 2009 to support regulatory review of the company's pending application to market NEBIDO as the first long-acting testosterone preparation available in the United States.

Octreotide implant is in Phase III clinical testing for the treatment of acromegaly, a chronic hormone disorder resulting from excessive production of growth hormone. It utilizes HYDRON polymer technology to deliver six months of octreotide.

VANTAS is a soft, flexible hydrogel implant currently marketed in the U.S., Canada, Argentina, Europe and Asia for the palliative treatment of advanced prostate cancer. The product utilizes the company's HYDRON polymer technology to allow for controlled delivery of histrelin over a 12-month period.

Indevus also has a strong pipeline of additional development projects and is preparing to reintroduce VALSTARTM for the treatment of bacillus Calmette-Guerin (BCG)-refractory bladder cancer patients who are not candidates for bladder removal (cystect
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Atlanta, Georgia (PRWEB) May 04, 2015 Each ... the country to raise funds and awareness for breast cancer. ... Plastic Surgery will be featured as the entertainment sponsor for ... the Cure” on May 9 at the Lenox Square Mall. ... year’s Atlanta race, and to raise $1.2 million. Perimeter Plastic ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be ... Group (RUG) Conference in Baltimore, MD from May 11 ... Group provides an opportunity for clients to gather to ... , In addition to sponsoring the event, TROY Healthcare ... RUG Conference. Attendees can stop by the TROY booth ...
(Date:5/4/2015)... May 04, 2015 In May of 2010, ... his own life. In the wake of this tragedy, Ty’s ... an organization that exposes the grim reality of bullying and ... platform for Kirk and Laura to share their story and ... from happening to another family — a mission that took ...
(Date:5/4/2015)... 04, 2015 EY today announced that ... a finalist for the EY Entrepreneur Of The Year® ... awards program recognizes entrepreneurs who demonstrate excellence and extraordinary ... personal commitment to their businesses and communities. Mr. ... of independent judges. Award winners will be announced ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 New findings ... Brain Tumor Association (ABTA) show that people diagnosed with ... and treatment options, including clinical trials, at the time ... to make difficult decisions about their course of treatment. ... of the first nationwide brain tumor volunteer network, the ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... center, which can go awry , , WEDNESDAY, Jan. 23 ... part of the brain handles what might be called ... lead scientists closer to more effective treatments for a ... brain region is helpful because it provides insight into ...
... fingertips to tap or press a surface is essential ... use a BlackBerry or an iPhone. But researchers ... seemingly trivial action is the result of a complex ... nervous system and muscles of the hand. , ...
... 23, 2008RNA interference (RNAi) represents an innovative new strategy ... associated with disease processes, and a series of review ... RNAi and microRNAs will begin with two review papers ... of Human Gene Therapy, a peer-reviewed journal published by ...
... increased by 18.0% to ... - Medical enrollment grew by 708,000 members during 2007, - Selling, general and ... by 120 basis points during the year, - Operating cash flow exceeded $4.3 billion for the year, or 1.3 ... income, - Company reiterates ...
... KIRKLAND, Wash., Jan. 23 "A failing mind, not ... today," says Cameron,Truesdell, CEO of LTC Financial Partners, the ... be, so we,re going to give,our clients information to ... offering a free guidebook and web links to helpful ...
... for Gestiva(TM) Anticipated in Calendar 2008, Gestiva(TM), is Designated ... Prevention ... in Singleton Pregnancies, ST. LOUIS, Jan. 22 ... company that,develops, manufactures, acquires and markets technology-differentiated,branded and generic/non-branded ...
Cached Medicine News:Health News:Specific Brain Region Governs Problem-Solving Skills 2Health News:Specific Brain Region Governs Problem-Solving Skills 3Health News:What gives us fingertip dexterity? 2Health News:What gives us fingertip dexterity? 3Health News:The RNA drug revolution -- a new approach to gene therapy 2Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 2Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 3Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 4Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 5Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 6Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 7Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 8Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 9Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 10Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 11Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 12Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 13Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 14Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 15Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 16Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 17Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 18Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 19Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 20Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 21Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 22Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 23Health News:Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 3Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 4Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 5
(Date:5/4/2015)... May 4, 2015 MEI Pharma, Inc. ... on the clinical development of novel therapies for ... effects of the Company,s investigational drug candidate ME-344 ... when combined with a tyrosine-kinase inhibitor (TKI). In ... be a potent inhibitor of mitochondrial oxidative phosphorylation ...
(Date:5/4/2015)... 4, 2015  Geneia, a company of experienced ... to improve healthcare efficiencies, today announced a first-of-its-kind ... (BNRC) use Geneia,s advanced analytics solution coupled ... quality and lower the cost of patient care. ... claims and utilization data from multiple sources to ...
(Date:5/4/2015)... 2015 Intarcia Therapeutics, Inc. ... into the newly created role of Chief ... pharmaceutical executive with world-class experience – most recently ... service at industry leaders such as Pfizer and ... range of therapeutic areas, including: cardiovascular, metabolic, oncology, ...
Breaking Medicine Technology:MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4
... super series slit ... Examination through small ... fundus diagnostic capability, ... potential field of ...
... Volk's super ... biomicroscopy lenses. General ... Provide unprecedented fundus ... addressing maximum potential ...
Volk indirect lenses. General diagnosis / small pupil examinations....
Volk indirect lenses. General diagnosis & treatment....
Medicine Products: